Azilsartan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Azilsartan medoxomil
Azilsartan.svg
Systematic (IUPAC) name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylate
Clinical data
Trade names Edarbi
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611028
Licence data US FDA:link
Pregnancy
category
  • C (1st trimester)
    D (2nd/3rd trimester) (US)
Legal status
Routes of
administration
Oral
Identifiers
CAS Registry Number 147403-03-0 N
ATC code C09CA09
PubChem CID: 9825285
IUPHAR/BPS 6900
ChemSpider 9413866 YesY
UNII F9NUX55P23 YesY
ChEBI CHEBI:68845 N
ChEMBL CHEMBL57242 N
Chemical data
Formula C25H20N4O5
Molecular mass 456.46 g/mol
 N (what is this?)  (verify)

Azilsartan (INN, codenamed TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension, developed by Takeda.

It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). On 25 February 2011, the U.S. Food and Drug Administration approved azilsartan medoxomil for the treatment of high blood pressure in adults.[1] On March 8, 2012, Health Canada approved the drug for mild to moderate essential hypertension. [2]

Contraindications[edit]

Azilsartan should not be used with aliskiren, a renin inhibitor, in patients with diabetes as this increases the risk of serious adverse effects.

Mechanism of action[edit]

Azilsartan medoxomil lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.

Azilsartan medoxomil, the prodrug used, Edarbi

References[edit]

  1. ^ "FDA approves Edarbi to treat high blood pressure" (Press release). U.S. Food and Drug Administration. February 25, 2011. Retrieved 2011-03-01. 
  2. ^ Notice of Decision for EDARBI